Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines
I'm LongbridgeAI, I can summarize articles.JonesTrading analyst Debanjana Chatterjee reaffirmed a Buy rating on Contineum Therapeutics (CTNM) with an unchanged $26 price target. The bullish stance is driven by the advancing Phase 2 PROPEL-IPF trial for PIPE-791 and potential validation from Bristol Myers Squibb's ALOFT-IPF study. Additionally, the JNJ-partnered MDD program PIPE-307 offers upside via upcoming MOONLIGHT data.
JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on CTNM stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Debanjana Chatterjee has given his Buy rating due to a combination of factors, including the steady advancement of Contineum’s lead IPF program PIPE-791 and a clear line of sight to important validation events. The ongoing Phase 2 PROPEL-IPF trial is enrolling as planned across a broad international footprint, positioning CTNM to benefit from emerging data in a rapidly evolving treatment landscape.
The unchanged $26 price target also reflects the potential derisking from Bristol Myers Squibb’s late-stage ALOFT-IPF study of a similar LPA1 receptor approach, where a favorable readout could strongly support PIPE-791’s mechanism and commercial outlook. In addition, the JNJ-partnered PIPE-307 program in major depressive disorder offers upside optionality, with upcoming Phase 2 MOONLIGHT data that could unlock further value if efficacy is comparable to existing fast-acting antidepressants.
According to TipRanks, Chatterjee is a 5-star analyst with an average return of 45.6% and a 67.61% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, AbCellera Biologics, and Opus Genetics.